Isabel Jaco

Senior Principal Scientist & Group leader - Radioligand Therapy Drug Discovery Novartis AG

Seminars

Tuesday 11th November 2025
Radioligand Therapy: Successes & Future Challenges
8:30 am

Radiopharmaceuticals are on the rise worldwide. Join key players to explore how Europe is driving progress in this exciting field – and what it means for the future of cancer care around the world.

  • Demonstrating significant progression-free survival benefits for mCRPC patients treated with Pluvicto
  • The success of Pluvicto in improving progression-free survival compared to standard care
  • New challenges and opportunities in RLT: new targets, combinations
Isabel Jaco, Senior Principal Scientist & Group leader - Radioligand Therapy Drug Discovery, Novartis AG
View all Speakers
View Event Brochure